Please provide your email address to receive an email when new articles are posted on . The FDA has granted priority review to a supplemental new drug application for Linzess for the treatment of ...
Hosted on MSN
Ibsrela vs. Linzess: How Do They Compare for IBS-C?
Irritable bowel syndrome with constipation (IBS-C) is characterized by symptoms such as irregular bowel movements, abdominal pain, and bloating. The U.S. Food and Drug Administration (FDA) has ...
The U.S. Food and Drug Administration (FDA) granted priority review to AbbVie (NYSE:ABBV) and Ironwood Pharmaceuticals' (NASDAQ:IRWD) application seeking expanded approval of Linzess (linaclotide) to ...
(RTTNews) - Ironwood Pharmaceuticals, Inc. (IRWD) announced the FDA has granted Priority Review to the supplemental New Drug Application for LINZESS for the treatment of children and adolescents ages ...
Ironwood Pharmaceuticals IRWD announced that the FDA has accepted and granted priority review to a supplemental new drug application (sNDA), seeking expanded use of Linzess (linaclotide) for children ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Linzess, the first therapy for pediatric functional constipation in patients aged 6 to 17 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback